相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。GLP-1/GIP/glucagon receptor triagonism gets its try in humans
Brian Finan et al.
CELL METABOLISM (2022)
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart et al.
CELL METABOLISM (2022)
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes The SURPASS-5 Randomized Clinical Trial
Dominik Dahl et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
Valentina Pirro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
The incretin/glucagon system as a target for pharmacotherapy of obesity
Stefano Del Prato et al.
OBESITY REVIEWS (2022)
Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
Maria Chiara Pelle et al.
LIFE-BASEL (2022)
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed Sattar et al.
NATURE MEDICINE (2022)
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
Tim Heise et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis
Yan Tang et al.
FRONTIERS IN PHARMACOLOGY (2022)
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Vivek P. Chavda et al.
MOLECULES (2022)
What's preventing us from curbing the obesity crisis?
[Anonymous]
LANCET DIABETES & ENDOCRINOLOGY (2022)
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Nobuya Inagaki et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coskun et al.
CELL METABOLISM (2022)
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Shweta Urva et al.
LANCET (2022)
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
Hiddo J L Heerspink et al.
Lancet Diabetes & Endocrinology (2022)
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr et al.
MOLECULAR METABOLISM (2022)
Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Ricardo J. Samms et al.
MOLECULAR METABOLISM (2022)
WEIGHT LOSS EFFECT OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN PATIENTS WITH OBESITY WITHOUT DIABETES: A SYSTEMATIC REVIEW
K. G. Pratama et al.
ACTA ENDOCRINOLOGICA-BUCHAREST (2022)
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr et al.
MOLECULAR METABOLISM (2022)
HbA(1c) Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
M. Angelyn Bethel et al.
DIABETES CARE (2021)
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang et al.
CELL METABOLISM (2021)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato et al.
LANCET (2021)
The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
Makoto Fukuda
DIABETES (2021)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock et al.
LANCET (2021)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik et al.
LANCET (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A. Killion et al.
ENDOCRINE REVIEWS (2020)
The early history of GIP 1969-2000: From enterogastrone to major metabolic hormone
Vincent Marks
PEPTIDES (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors
Sanaz Darbalaei et al.
BIOCHEMICAL PHARMACOLOGY (2020)
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes
Jennifer Trujillo
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)
Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study
Niina Matikainen et al.
DIABETES OBESITY & METABOLISM (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients
Francesca Mallamaci et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
Laerke S. Gasbjerg et al.
DIABETES (2019)
Short-termblood pressure variability in nondialysis chronic kidney disease patients: correlates and prognostic role on the progression of renal disease
Silvio Borrelli et al.
JOURNAL OF HYPERTENSION (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
A rapidly acting glutamatergic ARC→PVH satiety circuit postsynaptically regulated by α-MSH
Henning Fenselau et al.
NATURE NEUROSCIENCE (2017)
Novel GLP-1R/GIPR co-agonist twincretin is neuroprotective in cell and rodent models of mild traumatic brain injury
Ian A. Tamargo et al.
EXPERIMENTAL NEUROLOGY (2017)
Mechanisms, Pathophysiology, and Management of Obesity
Nai-Wei Sheu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Health Effects of Overweight and Obesity in 195 Countries over 25 Years
Ashkan Afshin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Central administration of GLP-1 and GIP decreases feeding in mice
Cherl NamKoong et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation
Neil M. Iyengar et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy
Luca De Nicola et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2015)
European Guidelines for Obesity Management in Adults
Volkan Yumuk et al.
OBESITY FACTS (2015)
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Anna Secher et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society
Michael D. Jensen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
Su-Jin Kim et al.
PLOS ONE (2012)
Administration of an acylated GLP-I and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity
Victor A. Gault et al.
CLINICAL SCIENCE (2011)
GIP-Dependent Expression of Hypothalamic Genes
S. Ambati et al.
PHYSIOLOGICAL RESEARCH (2011)
GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene
Su-Jin Kim et al.
JOURNAL OF LIPID RESEARCH (2010)
The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets
R. Lupi et al.
REGULATORY PEPTIDES (2010)
Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain
Jenny Nyberg et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2007)
Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice
Nigel Irwin et al.
JOURNAL OF PEPTIDE SCIENCE (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness
D Delmeire et al.
BIOCHEMICAL PHARMACOLOGY (2004)